Glenview Trust co Increases Stock Position in Zoetis Inc. (NYSE:ZTS)

Glenview Trust co lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 10.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,221 shares of the company’s stock after acquiring an additional 410 shares during the period. Glenview Trust co’s holdings in Zoetis were worth $688,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of ZTS. Raymond James Financial Inc. purchased a new position in shares of Zoetis during the fourth quarter worth approximately $196,651,000. Amundi grew its position in shares of Zoetis by 46.2% during the fourth quarter. Amundi now owns 2,748,719 shares of the company’s stock worth $453,355,000 after acquiring an additional 867,993 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of Zoetis by 296.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock worth $144,917,000 after acquiring an additional 665,331 shares during the last quarter. Nordea Investment Management AB lifted its holdings in shares of Zoetis by 38.3% during the fourth quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock worth $336,266,000 after purchasing an additional 572,511 shares during the period. Finally, Holocene Advisors LP acquired a new stake in shares of Zoetis during the third quarter worth $110,809,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ZTS. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. Morgan Stanley decreased their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Finally, Stifel Nicolaus reduced their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average price target of $215.90.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is owned by corporate insiders.

Zoetis Trading Up 2.6 %

NYSE:ZTS opened at $165.39 on Tuesday. The company has a market capitalization of $74.06 billion, a PE ratio of 30.24, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.33. The stock has a fifty day simple moving average of $166.82 and a 200-day simple moving average of $175.97.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.21%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.